Related Experiment Videos
Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
Abstract:
Cefmenoxime is an aminothiazolyl cephalosporin administered intravenously or intramuscularly. Like other 'third-generation' cephalosporins it is active in vitro against most common Gram-positive and Gram-negative pathogens, is a potent inhibitor of Enterobacteriaceae (including beta-lactamase-producing strains), and is resistant to hydrolysis by beta-lactamases. Cefmenoxime has a high rate of clinical efficacy in many types of infection and is at least equal in clinical and bacteriological efficacy to several other cephalosporins in urinary tract infections, respiratory tract infections, postoperative infections and gonorrhoea. Cefmenoxime, like latamoxef, cefoperazone and cefamandole, has an N-methyltetrazole side chain at the 3-position of the cephalosporin nucleus and thus possesses the potential for producing hypoprothrombinaemic bleeding and disulfiram-like reactions. However, these reactions have been reported very rarely and the antibacterial is generally well tolerated. It is likely that cefmenoxime will most closely resemble cefotaxime and ceftizoxime in therapeutic profile and usefulness.
Insights
Cefmenoxime, a third-generation cephalosporin antibiotic, demonstrates broad-spectrum activity against Gram-positive and Gram-negative bacteria. It shows high clinical efficacy in various infections and is generally well-tolerated, with rare adverse effects.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Cefmenoxime is an aminothiazolyl cephalosporin antibiotic.
- It belongs to the third-generation cephalosporins class.
- Administered via intravenous or intramuscular routes.
Purpose of the Study:
- To evaluate the in vitro activity and clinical efficacy of cefmenoxime.
- To compare cefmenoxime with other cephalosporins in treating various infections.
- To assess the safety profile of cefmenoxime, including potential adverse reactions.
Main Methods:
- In vitro susceptibility testing against common Gram-positive and Gram-negative pathogens.
- Clinical trials assessing efficacy in urinary tract, respiratory tract, postoperative infections, and gonorrhea.
- Monitoring for adverse events, specifically hypoprothrombinemia and disulfiram-like reactions.
Main Results:
- Cefmenoxime exhibits potent in vitro activity against Enterobacteriaceae, including beta-lactamase-producing strains.
- It is resistant to hydrolysis by beta-lactamases.
- Clinical efficacy is high and comparable to other cephalosporins in various infections.
Conclusions:
- Cefmenoxime is an effective and generally well-tolerated antibiotic for treating a range of bacterial infections.
- Potential adverse effects associated with its N-methyltetrazole side chain are rare.
- Cefmenoxime's therapeutic profile is expected to be similar to cefotaxime and ceftizoxime.